Dilip Samarapungavan

Dr. Dilip Samarapungavan

Transplant Surgery
3535 West 13 Mile Road, Suites 644, 
Royal Oak, MI 
On Staff At
Accepting New Patients
38 Years of Experience
3535 West 13 Mile Road, Suites 644, 
Royal Oak, MI 
OverviewInsuranceLocationsClinical Research

Overview

Dilip Samarapungavan is a Transplant Surgeon in Royal Oak, Michigan. Dr. Samarapungavan has been practicing medicine for over 38 years and is rated as an Experienced provider by MediFind in the treatment of Magnesium Deficiency. His top areas of expertise are Chronic Antibody-Mediated Rejection, End-Stage Renal Disease (ESRD), Polycystic Kidney Disease, Febrile Neutropenia, and Kidney Transplant. Dr. Samarapungavan is currently accepting new patients.

His clinical research consists of co-authoring 10 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years.

Graduate Institution
Kilpauk Medical College Dr M.G.R. Medical University, 1988
Residency
Henry Ford Hospital
Specialties
Transplant Surgery
Licenses
Internal Medicine in MI
Board Certifications
American Board Of Internal Medicine
American Board Of Internal Medicine
Fellowships
Henry Ford Hospital
Hospital Affiliations
Corewell Health William Beaumont University Hospital
Languages Spoken
English
Hindi
Russian
Tamil
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

Corewell Health Transplant Professional Services - 3535 W 13 Mile Rd
3535 West 13 Mile Road, Suites 644, Royal Oak, MI 48073

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir
A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir
Enrollment Status: Completed
Publish Date: November 03, 2021
Intervention Type: Drug
Study Phase: Phase 3

10 Total Publications

Glomerular epithelial cell differentiation and aberration evaluated using PAX8 and WT1 immunostains.
Glomerular epithelial cell differentiation and aberration evaluated using PAX8 and WT1 immunostains.
Journal: Ultrastructural pathology
Published: November 28, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Samarapungavan's expertise for a condition
ConditionClose
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile